The Secret Life of a Prescription: What Happens Between the Doctor's Pen and the Pharmacy Counter
May 31, 2026
A prescription starts in the exam room as an act of trust. The clinician listens, examines, considers risks and benefits, and selects a medication. Even though doctors now use keyboards instead of pens, the idea remains the same: one person is trying to help another survive, heal, or live with less pain.
For many patients, getting a prescription is not the end of their medical visit. It is the start of another process. The medicine has to go through a private system that decides if the drug is covered, where it can be filled, what the patient will pay, and what payments move between companies behind the scenes. A doctor may believe they have prescribed a medicine. The patient may expect to pick it up. But between those two steps lies one of the least-understood parts of American medicine: the pharmacy benefit manager.
The system is huge. In 2024, the United States spent $5.3 trillion on health care, which was 18 percent of the country’s GDP. Prescription drugs alone cost $467 billion. (1) At the same time, Americans owed at least $220 billion in medical debt. (2) These numbers are not merely statistics. They show that in this country, illness often comes with another problem: financial vulnerability.
Prescription drugs make this financial risk especially clear. They are where years of scientific work turn into a purchase at the counter. A medication might be the result of decades of research, the best treatment for a disease, and the difference between stability and crisis. But when patients get to the pharmacy, the question is often simple: Can I afford this? In the Federal Trade Commission's 2024 PBM inquiry, nearly 30 percent of Americans reported rationing or skipping their medicines due to high costs. (3) For doctors, that number is more than a statistic. It is a quiet failure that can happen even when the prescription is written correctly.
This is the hidden journey of a prescription. Medicine does not go straight from doctor to patient. It passes through formularies, rebates, pharmacy networks, rules, payment schedules, and business relationships that most patients never see and many doctors only partly understand. Pharmacy benefit managers did not create high drug prices, and they are not the only ones responsible. Drug makers set the prices. Insurers and employers design the benefits. Regulators allowed the system to become more complex. Patients are caught in the middle. But PBMs became the ones who learned how to control the process.
The useful middleman
Early PBMs were not big companies. They were created to handle paperwork. As prescription drug coverage expanded in the late twentieth century, insurers and employers needed a way to process claims, verify eligibility, manage payments, and establish networks. Back then, with paper forms and slow payments, a patient might show up at the pharmacy before anyone knew what the plan would cover. The first PBMs made this process clearer.
The story is more practical than sinister. PAID Prescriptions began in the U.S. in 1965, and the Pharmaceutical Card System began processing claims in 1969. By the late 1960s, these early companies were already helping with reimbursements and pharmacy participation. (4) They offered something valuable: real-time claim processing, predictable payments, and a link between pharmacies and health plans.
Today’s prescription benefits require systems to process claims, verify eligibility, and manage pharmacy networks, formularies, and utilization. PBMs handle these jobs now. They negotiate rebates and discounts with drug makers, process claims, pay pharmacies, set up networks, design formularies, create rules, and help decide what patients pay. (5) At best, they act as a balance to drug manufacturers in a market without a single national buyer.
That argument should be taken seriously. Without some way to manage purchases, big employers and insurers would have to deal with drug companies one plan at a time, and prices could be even higher. Formularies can guide people to cheaper options. When used effectively, prior authorization can prevent waste and unsafe prescribing. Negotiated discounts can lower premiums or total plan costs. A system without PBMs would not suddenly become simple.
The problem is that helpful organizations can change in risky ways. PBMs started as administrators but became powerful economic players. The company that handled claims began to control which drugs were covered, which pharmacies were in the network, how much pharmacies were paid, and the financial deals behind drug lists. What originated as a simple claims job became a gatekeeping role. Prescriptions were no longer exclusively accepted or denied based on the plan. They were sent through a system with hidden incentives, often unclear even to the employers paying for the benefits.
Calling PBMs 'middlemen' does not capture what they do now. In the biggest companies, PBMs are linked to insurers, mail-order and specialty pharmacies, drug lists, rebate contracts, and the data that tie everything together. At this stage, PBMs are more like private gatekeepers of access than simple intermediaries.
When the discount became the business
Rebates are at the heart of the system. In theory, they make sense: a manufacturer sets a list price, a PBM negotiates a discount for better placement on a drug list, and the health plan saves money. Ideally, these savings help patients, employers, or taxpayers.
But in reality, the rebate system led to some odd and unfair results. The list price of a drug could go up, even if the final price after rebates went down. A health plan might get a big discount later, but a patient whose costs are based on the list price would still pay more at the pharmacy. While the plan sponsor hears about big savings, the patient might see a bigger bill.
This goes beyond being an accounting detail. According to Drug Channels Institute, the difference between what brand-name drugs sell for at list price and what manufacturers actually receive after rebates and discounts reached $356 billion in 2024. (6) While this isn't an official government number, many people rely on it because it highlights a key point: the price patients and the public see is often not the real price that decides the deal. This gap has become its own financial system.
Insulin is the clearest and most tragic example. Alec Smith, a 26-year-old from Minnesota with type 1 diabetes, died in 2017 after he lost his mother's insurance and had to ration insulin he couldn't afford. Minnesota later named its insulin affordability law after him. (7) While his story doesn't explain everything about the insulin market, it shows what can happen when someone faces a high list price with no bargaining power and no time.
In 2024, the FTC sued the three largest PBMs - Caremark Rx, Express Scripts, and OptumRx - and their affiliated group purchasing organizations, alleging that they used anticompetitive and unfair rebate practices to inflate insulin list prices, impair access to lower-list-price products, and shift costs to vulnerable patients.8 The complaint alleged that the average list price of Lilly's Humalog rose from $21 in 1999 to more than $274 in 2017, an increase of more than 1,200 percent.8 The FTC was careful to say that manufacturers also played a troubling role; drugmakers set the prices and participated in the system. But the agency's theory was that PBM formulary leverage rewarded high-list-price, high-rebate products even when lower-list-price alternatives were available. (8)
These legal claims remain allegations until they are settled. Still, the way the system works matches what many patients go through. A manufacturer raises the list price, a PBM negotiates a bigger rebate, and the plan sponsor might save money later. The PBM can earn fees based on the size of the rebate. But the patient at the pharmacy regularly pays the full list price before any rebates are applied. So, the price people see can go up, even when the system says it's saving money.
Manufacturers' actions showed how much prices depend on the system. In 2023, Eli Lilly said it would cut the list price of Humalog and Humulin by 70 percent and lower the price of its non-branded insulin lispro to $25 per vial. (9) This didn't mean insulin was ever cheap to make or easy to distribute. Instead, it showed that list prices are driven by the market, not just by the cost of science.
This is the most difficult part of the PBM story to explain because the system can look different depending on your role. Employers might really get rebates. Premiums might be lower than they would have been otherwise. PBMs may pass most manufacturer rebates to many clients, according to the industry. (10) But a patient with a deductible, coinsurance, no insurance, or a drug not covered by their plan can still be hurt by high list prices and complicated rules. The system as a whole might improve, but individuals can still suffer.
Concentration and the owned channel
The rebate system became more consequential because PBM power became concentrated. According to KFF's 2026 summary of federal PBM efforts, drawing on FTC data, the top three PBMs - OptumRx, Express Scripts, and CVS Caremark - managed 79 percent of prescription-drug claims on behalf of 270 million people in 2023.5 A 2026 JAMA Health Forum study found that PBM concentration varied by state and payer type, but highly concentrated PBM markets accounted for 93.7 percent of Medicaid managed-care retail prescriptions and 74.8 percent of Medicare Part D retail prescriptions. (11)
This isn't just a case of many small players. Instead, a few big companies ended up controlling how most prescriptions move through the health system. Their size gave them the power to negotiate with manufacturers, which was the main reason they were allowed to grow. But being so large also allows them to decide which drugs are preferred, which pharmacies are included, where specialty prescriptions are handled, and what information is shared with plan sponsors and patients.
Then, concentration became vertical integration. CVS Health owns CVS Caremark and Aetna and operates a national retail pharmacy chain. Cigna owns Express Scripts. UnitedHealth Group owns OptumRx. The FTC's 2024 report emphasized that leading PBMs were vertically integrated with mail-order and specialty pharmacies, and its second report noted that pharmacies affiliated with the Big Three received 68 percent of specialty-drug dispensing revenue in 2023, up from 54 percent in 2016. (12)
There is a straightforward argument for vertical integration. If one company manages the plan, negotiates contracts, processes claims, and dispenses the drug, the system might become more coordinated. Administrative hassles could decrease, and a bigger scale might lower costs. Regulators often accepted this reasoning during the years of mergers.
But integration also changes what companies care about. When the same company designs the drug list and owns the pharmacy, decisions about where to fill a prescription can be driven by profit rather than coverage. Patients might be told to use a certain mail-order or specialty pharmacy, not because it's medically needed, but because the benefit design makes it easier for the company. Independent pharmacies feel squeezed, and patients may face fewer choices, longer waits, or misunderstandings about who is answerable if something goes wrong.
The latest evidence is complicated, and it should be treated honestly. In May 2026, the Department of Health and Human Services Office of Inspector General reported that, for selected Medicare Part D drugs, the net cost of drugs was similar for vertically integrated sponsors and other sponsors. The report also found that vertically integrated sponsors often paid pharmacies more upfront but took back more later through rebates and fees; that data limitations prevented the OIG from fully assessing subsequent pharmacy payment adjustments; and that enrollees in vertically integrated Part D plans generally paid lower premiums but substantially higher out-of-pocket drug costs. (13)
This finding doesn't let vertical integration off the hook. Instead, it helps us see the real issue. A plan might seem cheaper when you look at premiums, but a sick patient could end up paying more when they need medicine. The overall cost might look the same, but getting access to drugs could become harder. The real question is whether shared ownership allows companies to shift money, patients, and risk in ways that are hidden from those most affected.
The ledgers nobody could see
Opacity is not an accident in this market. It is a business condition. The lack of transparency isn't a mistake in this market. It's part of how the business works. A single prescription can have many prices: the manufacturer's list price, what the plan pays, what the pharmacy receives, the rebate paid later, the fee a middleman keeps, and what the patient pays out of pocket. Each group sees a different set of numbers. PBMs are among the few who can see several of these at once. In an arrangement, a PBM charges the health plan a single amount for a drug, reimburses the pharmacy a lower amount, and keeps the difference. KFF describes the concern plainly: the plan sponsor may not know the amount paid to the pharmacy and therefore cannot know the spread. (5) In Medicaid and employer plans, that gap became a target of reform because it made the PBM's margin dependent not simply on service fees but on the distance between two hidden prices.
The specialty-drug market boosted the numbers. In January 2025, the FTC's second interim report examined specialty generic drugs dispensed from 2017 through 2022 for commercial and Medicare Part D members whose benefits were managed by the Big Three PBMs. FTC staff reported that those PBMs and their affiliated pharmacies generated more than $7.3 billion in dispensing revenue above the National Average Drug Acquisition Cost (NADAC) for the drugs analyzed. The report also found that revenue above NADAC grew at a compound annual rate of more than 42 percent from 2017 to 2021, and that the PBMs earned $1.4 billion of spread-pricing income on the analyzed specialty generics. (12)
These were not minor drugs. The FTC listed medications for cancer, heart disease, multiple sclerosis, HIV, transplant care, and other serious illnesses. (12) Specialty drugs are often among the few options available to patients. They are costly, essential for treatment, and difficult to manage. A delay in getting a refill or being forced to switch pharmacies can disrupt treatment.
Another layer emerged through affiliated group purchasing organizations, also known as rebate aggregators. Zinc Health Services, Ascent Health Services, and Emisar Pharma Services were included in the FTC's PBM inquiry and named in the insulin litigation.8 The Department of Labor's proposed 2026 fee-disclosure rule specifically noted concerns about compensation flowing through affiliates, agents, subcontractors, and rebate aggregators or GPOs, including some formed outside the United States. (14) The existence of such entities does not, by itself, prove wrongdoing. But it does reveal how far the financial architecture had moved from the counter where the patient stands.
The simplest critique of PBMs is that they keep things secret. But the bigger issue is that secrecy can make money. When profits depend on rebates, spreads, fees, owning pharmacies, or special contracts, the market gives companies reasons to keep them hidden.
By 2026, PBMs had become a rare target that brought together unlikely allies in American health care: independent pharmacists, patient advocates, antitrust reformers, populist conservatives, employer groups, and some doctors. They didn't agree on every solution, but they all saw that the prescription drug system had become too hard to understand—even for experts.
The FTC's PBM inquiry, begun in 2022, produced two major staff reports, the insulin complaint, and a series of enforcement actions. In February 2026, the FTC announced a settlement with Express Scripts resolving the agency's insulin lawsuit against that company. Under the proposed consent order, Express Scripts agreed to changes, including offering plan sponsors a model in which member out-of-pocket expenses would be based on net cost rather than inflated list price, allowing transition away from rebate guarantees and spread pricing, and delinking manufacturer compensation to Express Scripts from list prices as part of its standard offering. (15)
The case wasn't over yet. In March 2026, CVS Health said its Caremark unit had reached a proposed settlement with the FTC, but the final details were still being worked out. OptumRx was still in the midst of legal proceedings.1617 The legal status is important because it shows that some serious accusations are still being debated. Still, the trend is clear: regulators are no longer treating PBMs as neutral middlemen whose incentives can be left to private deals. In February 2026, federal PBM provisions were enacted as part of the Consolidated Appropriations Act, 2026. KFF summarized the law as delinking PBM compensation in Medicare Part D from drug prices, rebates, or discounts beginning in 2028; imposing new reporting requirements related to utilization, pricing, revenue, manufacturer contracts, affiliated pharmacies, and other business practices; and requiring PBMs to pass through 100 percent of rebates and discounts to ERISA-governed employer health plans.18 The Congressional Budget Office estimated a federal deficit reduction of only about $2.1 billion over ten years. This modest score says less about the moral stakes than about the difficulty of unwinding mature contractual systems. (18)
In January 2026, the Department of Labor proposed another change: a rule requiring companies that provide PBM services and related consulting to disclose to the people managing self-insured ERISA plans the amounts they are paid. The rule would cover a wide range of PBM services, like handling rebates, managing drug lists, running pharmacy networks, and processing claims. It would also require disclosure of payments to affiliates, agents, and subcontractors. (14) The idea is simple but important: those managing employee health plans should know how their vendors are paid.
The industry has also made its position clear. PCMA, the PBM trade group, says PBMs already pass almost all rebates to employers and that separating their pay from drug prices will hurt their ability to negotiate, raise premiums, and help drug makers. (10) This argument shouldn't be ignored. Drug companies are still a big part of the problem. If a policy weakens PBMs' bargaining power without controlling drug prices, patients could lose out. Transparency can be poorly designed, and reforms can end up helping other groups instead.
However, this defense doesn't address the main issue. It's not enough to talk about rebates given to employers or lower premiums overall. Patients don't experience the system as averages. Someone with cancer, diabetes, multiple sclerosis, HIV, or a transplant faces the system when they need help most. If the benefit design makes them pay a high list price, blocks cheaper options, forces them into certain pharmacies, or delays treatment with confusing rules, then the system has failed where it matters most.
States have tried to respond, but federal law complicates the effort. After the Supreme Court's 2020 decision in Rutledge v. Pharmaceutical Care Management Association, many reformers believed states had room to regulate PBM reimbursement practices. (19) More recent litigation has shown the limits. In April 2026, the Sixth Circuit held that Tennessee PBM provisions were preempted by ERISA as applied to a self-funded employer plan because they interfered with plan structure and uniform national administration. (20) The result is an uneven map: states can do some things, Congress must do others, and sophisticated companies can adapt faster than either.
What a prescription should not become
The case against PBMs is strongest when it avoids exaggeration. PBMs are not the sole cause of high drug prices. They did not create patent law, launch-price strategy, direct-to-consumer advertising, Medicare's fragmented purchasing history, or the wider American habit of paying more for health care than other wealthy countries. They perform real functions, and some version of those functions will be necessary in any large drug-benefit system.
The real issue is how the system works today. What started as a claims processor became a gatekeeper, then a negotiator, and finally was linked to insurers and pharmacies. Discounts turned into sources of profit. Now, a prescription can have one price in public, another in a contract, and yet another at the pharmacy counter.
As a doctor, I don't expect the drug-benefit system to be simple. Medicine itself is complex. Some drugs should be preferred, some prescriptions need review, and some prices need tough negotiation. But what I need—and what patients deserve—is a system where prescribing a drug doesn't secretly turn into a financial enigma with hidden rules.
Real reform should start with this idea. PBMs shouldn't make more money just because list prices go up. Rebates and discounts should help patients when their share of the cost is set, not just after the plan has processed the payment. Spread pricing should be banned when public funds are involved and fully disclosed elsewhere. Plan managers should have the right to audit and see all types of compensation. Drug lists should be based on clinical value and real costs, not just on rebates. Vertical integration should be judged by real evidence—like steering, pharmacy payments, patient costs, and delays in access—not just by promises of efficiency.
Most of all, the system should stop treating opacity as a neutral feature. Above all, the system needs to stop treating secrecy as just a normal part of business. In most markets, a price tells you something. In the American prescription drug market, price often hides the truth. The list price might not be the real price. What the patient pays might not include the discount. The pharmacy might be paid differently than the plan pays. The company running the benefit might make money in other ways. The result is a market where almost everyone claims to save money, but patients still can't afford their medicine. American medicine becomes an obstacle course. The patient leaves the exam room carrying hope, only to encounter a system that translates it into tiers, exceptions, preferred channels, hidden rebates, and bills that make no moral sense.
The hidden side of a prescription isn't hard to understand by accident. It's hidden because powerful groups benefit when regular people can't figure it out. But that can change. The complex system was built through contracts, mergers, benefit designs, and policy decisions. It can be changed the same way.
No reform will make American health care cheap overnight. But in a country that spends $5.3 trillion on health care, we should expect at least one simple thing: when a doctor writes a prescription and a patient needs medicine, the path from the doctor's pen to the pharmacy counter shouldn't be a hidden market that profits from the gap.
References and Notes
1. Centers for Medicare & Medicaid Services. National Health Expenditure Fact Sheet. January 14, 2026. Source
2. KFF. The Burden of Medical Debt in the United States. February 12, 2024. Source
3. Federal Trade Commission. FTC Releases Interim Staff Report on Prescription Drug Middlemen. July 9, 2024. Source
4. T. Joseph Mattingly II, David A. Hyman, and Ge Bai. Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy. JAMA Health Forum, November 3, 2023. Source
5. KFF. What to Know About Pharmacy Benefit Managers (PBMs) and Federal Efforts at Regulation. updated February 9, 2026. Source
6. Drug Channels Institute. Gross-to-Net Bubble Hits $356B in 2024 - But Growth Slows to 10-Year Low. July 15, 2025. Source
7. Minnesota Attorney General. No one should have to choose between affording their lives and affording to live. March 15, 2021. Source
8. Federal Trade Commission. FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices. September 20, 2024. Source
9. Eli Lilly and Company. Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month. March 1, 2023. Source
10. Pharmaceutical Care Management Association. Inside PBM Reform: Big Pharma's Big Win on Delinking. April 27, 2026. Source
11. Dima M. Qato, Yuting Chen, and Karen Van Nuys. Pharmacy Benefit Manager Market Concentration for Prescriptions Filled at Retail Pharmacies by State and Payer Type. JAMA Health Forum, February 6, 2026. Source
12. Federal Trade Commission. FTC Releases Second Interim Staff Report on Prescription Drug Middlemen. January 14, 2025. Source
13. HHS Office of Inspector General. Impacts of Vertical Integration in Medicare Part D on Sponsors' Drug Costs, Pharmacy Reimbursement, and Enrollee Cost Sharing. May 2026. Source
14. U.S. Department of Labor. Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure. Federal Register, January 30, 2026. Source
15. Federal Trade Commission. FTC Secures Landmark Settlement with Express Scripts to Lower Drug Costs for American Patients. February 4, 2026. Source
16. Reuters. CVS reaches insulin pricing settlement with FTC. March 24, 2026. Source
17. Federal Trade Commission. Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin): May 11, 2026 timeline item. May 11, 2026. Source
18. KFF. What to Know About Pharmacy Benefit Managers (PBMs) and Federal Efforts at Regulation. updated February 9, 2026. Source
19. Supreme Court of the United States. Rutledge v. Pharmaceutical Care Management Association, 592 U.S. 80. 2020. Source
20. McKee Foods Corp. v. BFP Inc.. Sixth Circuit decision on ERISA preemption of Tennessee PBM laws. April 7, 2026. Source